Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC).

To clarify the role of metabolic factors in endometrial carcinogenesis, we conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC), and examined the relation between prediagnostic plasma lipids, lipoproteins, and glucose, the metabolic syndrome (MetS; a cluster of metabolic factors) and endometrial cancer risk. Among pre- and postmenopausal women, 284 women developed endometrial cancer during follow-up. Using risk set sampling, 546 matched control subjects were selected. From conditional logistic regression models, high-density lipoprotein cholesterol (HDL-C) levels were inversely associated with risk body mass index (BMI)-adjusted relative risk (RR) for top versus bottom quartile 0.61 (95% confidence intervals (CI) 0.38-0.97), P(trend) = 0.02). Glucose levels were positively associated with risk (BMI-adjusted RR top versus bottom quartile 1.69 (95% CI 0.99-2.90), P(trend) = 0.03), which appeared stronger among postmenopausal women (BMI-adjusted RR top versus bottom tertile 2.61 (95% CI 1.46-4.66), P(trend) = 0.0006, P(heterogeneity) = 0.13) and never-users of exogenous hormones (P(heterogeneity) = 0.005 for oral contraceptive (OC) use and 0.05 for hormone replacement therapy-use). The associations of HDL-C and glucose with risk were no longer statistically significant after further adjustment for obesity-related hormones. Plasma total cholesterol, Low-density lipoprotein cholesterol (LDL-C), and triglycerides were not significantly related to overall risk. The presence of MetS was associated with risk (RR 2.12 (95% CI 1.51-2.97)), which increased with the number of MetS factors (P(trend) = 0.02). An increasing number of MetS factors other than waist circumference, however, was marginally significantly associated with risk only in women with waist circumference above the median (P(interaction) = 0.01). None of the associations differed significantly by fasting status. These findings suggest that metabolic abnormalities and obesity may act synergistically to increase endometrial cancer risk.

[1]  J. Chang-Claude,et al.  Serum levels of C‐peptide, IGFBP‐1 and IGFBP‐2 and endometrial cancer risk; Results from the European prospective investigation into cancer and nutrition , 2007, International journal of cancer.

[2]  H. Kajiyama,et al.  P-LAP/IRAP-induced cell proliferation and glucose uptake in endometrial carcinoma cells via insulin receptor signaling , 2007, BMC Cancer.

[3]  S. Larsson,et al.  Carbohydrate intake, glycemic index and glycemic load in relation to risk of endometrial cancer: A prospective study of Swedish women , 2006, International journal of cancer.

[4]  C. Runowicz,et al.  GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma , 2006, Modern Pathology.

[5]  J. Shaw,et al.  Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[6]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[7]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[8]  G. Jasienska,et al.  Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  D B Richardson,et al.  An incidence density sampling program for nested case-control analyses , 2004, Occupational and Environmental Medicine.

[10]  J. Vera,et al.  Differential regulation of glucose transporter expression by estrogen and progesterone in Ishikawa endometrial cancer cells. , 2004, The Journal of endocrinology.

[11]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[12]  F. Berrino,et al.  Prediagnostic levels of C‐peptide, IGF‐I, IGFBP ‐1, ‐2 and ‐3 and risk of endometrial cancer , 2004, International journal of cancer.

[13]  A. Furberg,et al.  Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort , 2003, International journal of cancer.

[14]  R. Kaaks,et al.  Obesity , Endogenous Hormones , and Endometrial Cancer Risk : A Synthetic Review 1 , 2002 .

[15]  Kenneth E Blick,et al.  Stability studies of twenty-four analytes in human plasma and serum. , 2002, Clinical chemistry.

[16]  A. Miller,et al.  Overweight, obesity and fat distribution in 50- to 64-year-old participants in the European Prospective Investigation into Cancer and Nutrition (EPIC) , 2002, Public Health Nutrition.

[17]  N E Day,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection , 2002, Public Health Nutrition.

[18]  F. Clavel-Chapelon,et al.  Physical activity of subjects aged 50–64 years involved in the European Prospective Investigation into Cancer and Nutrition (EPIC) , 2002, Public Health Nutrition.

[19]  F. Berrino,et al.  Fasting glucose is a risk factor for breast cancer: a prospective study. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  T. Sellers,et al.  Diabetes and endometrial cancer in the Iowa women's health study. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[21]  R. Kaaks,et al.  Energy balance and cancer: the role of insulin and insulin-like growth factor-I , 2001, The Proceedings of the Nutrition Society.

[22]  F. Larrea,et al.  Case–control study of diabetes, obesity, physical activity and risk of endometrial cancer among Mexican women , 2000, Cancer Causes & Control.

[23]  M. Sherman.  Theories of Endometrial Carcinogenesis: A Multidisciplinary Approach , 2000, Modern Pathology.

[24]  H. Adami,et al.  Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden) , 2000, Cancer Causes & Control.

[25]  P. Newcomb,et al.  Diabetes, body size, and risk of endometrial cancer. , 1998, American journal of epidemiology.

[26]  C. Stuart,et al.  Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. , 1998, American journal of obstetrics and gynecology.

[27]  T. Nicotera,et al.  Oxidative damage to DNA in diabetes mellitus , 1996, The Lancet.

[28]  T. Moy,et al.  The effect of fasting status on the determination of low-density and high-density lipoprotein cholesterol. , 1995, The American journal of medicine.

[29]  S. Haffner,et al.  Endogenous sex hormones: impact on lipids, lipoproteins, and insulin. , 1995, The American journal of medicine.

[30]  R. Hoover,et al.  Endometrial cancer risk in relation to serum lipids and lipoprotein levels. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[31]  F. Kronenberg,et al.  Effect of sample storage on the measurement of lipoprotein[a], apolipoproteins B and A-IV, total and high density lipoprotein cholesterol and triglycerides. , 1994, Journal of lipid research.

[32]  S. Shumak,et al.  Intraindividual variation in lipid and lipoprotein levels. , 1993, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[33]  U. Stenman,et al.  Relationship between carbohydrate metabolism and serum insulin-like growth factor system in postmenopausal women: comparison of endometrial cancer patients with healthy controls. , 1993, The Journal of clinical endocrinology and metabolism.

[34]  M. Law,et al.  Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies , 1991, Cancer Causes & Control.

[35]  N. Rifai,et al.  Postprandial Effect of a High Fat Meal on Plasma Lipid, Lipoprotein Cholesterol and Apolipoprotein Measurements , 1990, Annals of clinical biochemistry.

[36]  K. Frayn,et al.  Stability of Plasma Glucose during Storage , 1990, Annals of clinical biochemistry.

[37]  C. Chute,et al.  Effect of transport conditions on the stability of biochemical markers in blood. , 1989, Clinical chemistry.

[38]  M. Pike,et al.  The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. , 1988, British Journal of Cancer.

[39]  P N Demacker,et al.  Intra-individual variation of serum cholesterol, triglycerides and high density lipoprotein cholesterol in normal humans. , 1982, Atherosclerosis.

[40]  E. Barrett-Connor,et al.  ALTERED PLASMA LIPID AND LIPOPROTEIN LEVELS ASSOCIATED WITH ORAL CONTRACEPTIVE AND ŒSTROGEN USE Report from the Medications Working Group of the Lipid Research Clinics Program , 1979, The Lancet.

[41]  R. Krauss,et al.  Serum high-density-lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins. , 1978, The New England journal of medicine.

[42]  F. Nuttall,et al.  Postprandial plasma glucose, insulin, glucagon and triglyceride responses to a standard diet in normal subjects , 1976, Diabetologia.

[43]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[44]  H. Leather.  MEDICAL ASPECTS OF ORAL CONTRACEPTIVES. , 1965, Lancet.

[45]  C. Friedenreich,et al.  Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. , 2007, The Journal of clinical endocrinology and metabolism.

[46]  J. Chang-Claude,et al.  Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). , 2005, Journal of the National Cancer Institute.

[47]  Peter Devilee,et al.  Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2003 .

[48]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[49]  M. Sherman.  THEORIES OF ENDOMETRIAL CARCINOGENESIS , 2000 .

[50]  E. Stein,et al.  Estimating the Long-Term Effects of Storage at 2 70 °C on Cholesterol, Triglyceride, and HDL-Cholesterol Measurements in Stored Sera , 2000 .

[51]  R. Bergman,et al.  Central Role of the Adipocyte in Insulin Resistance , 1998, Journal of basic and clinical physiology and pharmacology.

[52]  E Riboli,et al.  The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. , 1997, International journal of epidemiology.

[53]  Y. Sun,et al.  Free radicals, antioxidant enzymes, and carcinogenesis. , 1990, Free radical biology & medicine.

[54]  R. Hiatt,et al.  Serum cholesterol and the incidence of cancer in a large cohort. , 1986, Journal of chronic diseases.

[55]  M. Modan,et al.  Increased rate of glucose intolerance in endometrial cancer--a community-based study. , 1984, Gynecologic and obstetric investigation.